OS Therapies Reports Third Quarter 2024 Financial Results and ...

Net loss per share in the third quarter of 2024 was $0.18 on 15.897 million weighted average shares outstanding compared to the third quarter of ...

"The third quarter was pivotal for OS Therapies as we completed our initial public offering and finished dosing the final patient enrolled in ...

OS Therapies Reports Third Quarter 2024 Financial Results and ...

OS Therapies (NYSE-A: OSTX) reported Q3 2024 financial results and business updates. The company completed its IPO and finished dosing the ...

OS Therapies Reports Third Quarter 2024 Financial Results and ...

OS Therapies, Inc. (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage cancer immunotherapy and antibody drug conjugate ...

Plus Therapeutics Reports Third Quarter 2024 Financial Results and ...

Per share information: Net loss per share of common stock - basic ; Net loss per share of common stock - basic, $ ; Weighted average number of ...

GH Research Reports Third Quarter 2024 Financial Results and ...

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression completed enrolment of the double-blind phase in Q3 2024 ...

Exelixis Announces Third Quarter 2024 Financial Results and ...

Total revenues for the quarter ended September 30, 2024 included net product revenues of $478.1 million , as compared to $426.5 million for the comparable ...

Elicio Therapeutics Reports Third Quarter 2024 Financial Results ...

We continue to anticipate completion of enrollment in Q4 2024 and expect to conduct a pre-planned interim analysis, including DFS, in H1 2025.

Elicio Therapeutics Reports Third Quarter 2024 Financial

We continue to anticipate completion of enrollment in Q4 2024 and expect to conduct a pre-planned interim analysis, including DFS, in H1 2025.

SELLAS Life Sciences Reports Third Quarter 2024 Financial Results ...

G&A Expenses: General and administrative expenses for the third quarter of 2024 were $3.0 million, compared to $3.5 million for the same period ...

Purple Biotech Reports Third Quarter 2024 Financial Results

Our cash runway now extends into the fourth quarter of 2025. We continue to advance our clinical assets and believe we will be soon well ...

AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS

Product sales grew 24%, driven by 29% volume growth, partially offset by 2% lower net selling price. Excluding sales from our Horizon Therapeutics (Horizon) ...

Geron Corporation Reports Third Quarter 2024 Financial Results ...

Strong execution in the first full quarter of U.S. launch, with net product revenue for RYTELO (imetelstat) of $28.2 million in the third ...

Candel Therapeutics Reports Third Quarter 2024 Financial Results ...

These decreases were partially offset by clinical development costs driven by increased manufacturing costs for CAN-2409 programs. Research and ...

IO Biotech Reports Third Quarter 2024 Financial Results and ...

The company recognized $0.6 million in research and development equity-based compensation for the three months ended September 30, 2024, ...

Lockheed Martin Reports Third Quarter 2024 Financial Results

Net earnings in the third quarter of 2024 were $1.6 billion , or $6.80 per share, compared to $1.7 billion , or $6 .73 per share, in the third quarter of 2023.

OS Therapies Reports Second Quarter 2024 Financial Results

OS Therapies, Inc., an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today reported financial results for the ...

Bristol Myers Squibb Reports Third Quarter Financial Results for 2024

Performance Reflects Continued Focus on Near-Term Execution and Building a Foundation for Long-Term Sustainable Growth Third Quarter ...

Regeneron Reports Third Quarter 2024 Financial and Operating ...

" Regeneron had a strong third quarter marked by 11% revenue growth. We continued to deepen the impact of our commercialized medicines this ...

Purple Biotech Reports Third Quarter 2024 Financial Results

("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune ...